Research ArticleTheranostics
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
Andrei Gafita, Marie Bieth, Markus Krönke, Giles Tetteh, Fernando Navarro, Hui Wang, Elisabeth Günther, Bjoern Menze, Wolfgang A. Weber and Matthias Eiber
Journal of Nuclear Medicine September 2019, 60 (9) 1277-1283; DOI: https://doi.org/10.2967/jnumed.118.224055
Andrei Gafita
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Marie Bieth
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
2Department of Informatics, Technical University Munich, Munich, Germany
Markus Krönke
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Giles Tetteh
2Department of Informatics, Technical University Munich, Munich, Germany
Fernando Navarro
2Department of Informatics, Technical University Munich, Munich, Germany
Hui Wang
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Elisabeth Günther
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Bjoern Menze
2Department of Informatics, Technical University Munich, Munich, Germany
Wolfgang A. Weber
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Matthias Eiber
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 60, Issue 9
September 1, 2019
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
Andrei Gafita, Marie Bieth, Markus Krönke, Giles Tetteh, Fernando Navarro, Hui Wang, Elisabeth Günther, Bjoern Menze, Wolfgang A. Weber, Matthias Eiber
Journal of Nuclear Medicine Sep 2019, 60 (9) 1277-1283; DOI: 10.2967/jnumed.118.224055
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
Andrei Gafita, Marie Bieth, Markus Krönke, Giles Tetteh, Fernando Navarro, Hui Wang, Elisabeth Günther, Bjoern Menze, Wolfgang A. Weber, Matthias Eiber
Journal of Nuclear Medicine Sep 2019, 60 (9) 1277-1283; DOI: 10.2967/jnumed.118.224055
Jump to section
Related Articles
Cited By...
- RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy
- Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0
- Using 68Ga-PSMA-11 PET/CT for Therapy Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer: Application of EAU/EANM Recommendations in Clinical Practice
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data
- Tumor Sink Effect in 68Ga-PSMA-11 PET: Myth or Reality?
- PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease
- Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
- Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer
- Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement